Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Total Valuation
Aldeyra Therapeutics has a market cap or net worth of $146.74M. The enterprise value is -$49.88T.
Market Cap$146.74M
Enterprise Value-$49.88T
Share Statistics
Aldeyra Therapeutics has 59,895,588 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,895,588
Owned by Insiders13.22%
Owned by Institutions35.38%
Financial Efficiency
Aldeyra Therapeutics’s return on equity (ROE) is -0.79 and return on invested capital (ROIC) is -71.49%.
Return on Equity (ROE)-0.79
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-71.49%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee0.00
Profits Per Employee-6.21M
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aldeyra Therapeutics is -5.31. Aldeyra Therapeutics’s PEG ratio is ―.
PE Ratio-5.31
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value4.18
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, Aldeyra Therapeutics had revenue of 0.00 and earned -55.85M in profits. Earnings per share was -0.94.
Revenue0.00
Gross Profit0.00
Operating Income-60.12M
Pretax Income-55.85M
Net Income-55.85M
EBITDA-60.12M
Earnings Per Share (EPS)-0.94
Cash Flow
In the last 12 months, operating cash flow was -12.47T and capital expenditures 0.00, giving a free cash flow of -12.47T billion.
Operating Cash Flow-12.47T
Free Cash Flow-12.47T
Free Cash Flow per Share-208.19K
Dividends & Yields
Aldeyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.13
52-Week Price Change-31.27%
50-Day Moving Average2.62
200-Day Moving Average4.81
Relative Strength Index (RSI)56.89
Average Volume (3m)1.07M
Important Dates
Aldeyra Therapeutics upcoming earnings date is Apr 30, 2026, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Aldeyra Therapeutics as a current ratio of 5.48, with Debt / Equity ratio of 0.74%
Current Ratio5.48
Quick Ratio5.48
Debt to Market Cap<0.01
Net Debt to EBITDA0.65
Interest Coverage Ratio-31.21
Taxes
In the past 12 months, Aldeyra Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aldeyra Therapeutics EV to EBITDA ratio is -4.29, with an EV/FCF ratio of -5.96.
EV to Sales0.00
EV to EBITDA-4.29
EV to Free Cash Flow-5.96
EV to Operating Cash Flow-5.96
Balance Sheet
Aldeyra Therapeutics has $90.06T in cash and marketable securities with $468.11B in debt, giving a net cash position of -$89.59T billion.
Cash & Marketable Securities$90.06T
Total Debt$468.11B
Net Cash-$89.59T
Net Cash Per Share-$1.50M
Tangible Book Value Per Share$1.19
Margins
Gross margin is 74.80%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin74.80%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aldeyra Therapeutics is $9.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.33
Price Target Upside250.75% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-47.28%